Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No....it's a BIG discount! Well maybe in the penny stock world its about right, but can you imagine say GOOG doing an offering at $100 while trading at $150?
Looks like CVM used them last year as well.
If I were a shareholder, I'd sure be looking closer at how the money is being used.
One can debate if a 15% offering was a bit discount. But this was a 40% discount. $2 when the stock was over $2.8 for the last several weeks.
And for a measly $7.2M? Generally when the discounts are large they raise enough cash to live off for a year or more.
I don’t think 25-28% is a HUGE discount. Actually pretty normal for a cash raise.
When you can’t borrow from conventional lenders, the offering is usually at a huge discount to current stock price in order to make the deal. It allows the buyer an opportunity to immediately profit if there are no restrictions on the new stock (and it’s totally possible the buyer or some of its affiliates had short positions as this deal was being negotiated) .
For the company, selling shares is a cheaper alternative than paying interest with cash you don’t have (not that any bank will lend additionally to them at this time).
Approval of their drug is the only way out of this mess. Even then, is the market large enough?
Geert hitting his personal ATM again.
Assuming that the potential buyer would pay a higher price for the shares.....
Well that ain't good for the shareholders
I think they are just too stupid to figure it out. You can dilute with less shares at a higher price…come on man!!
I absolutely get the need to raise money - but why do the keep undercutting the market by so much when they do so? Ugh.
Might have to use this opportunity to gather in some more shares at a discount next week though.
Gerty is famous for screwing the share holders. Looks like he did it again. A $2 offering when the stock was $3. Glad I am on the sidelines here, he has been screwing people for many many years.
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
February 09, 2024 08:30 AM Eastern Standard Time
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an offering of 3,875,000 shares of its common stock at an offering price of $2.00 per share, for gross proceeds of $7.75 million, before deducting underwriting discounts and offering expenses. All of the shares of common stock are being offered by the Company. The offering is expected to close on February 13, 2024, subject to satisfaction of customary closing conditions.
The Company intends to use the net proceeds from this offering to fund the continued development of Multikine*, for general corporate purposes, and working capital.
ThinkEquity is acting as sole book-running manager for the offering.
The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-265995), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 1, 2022 and declared effective on July 15, 2022. The offering will be made only by means of a written prospectus. A prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC on its website at www.sec.gov. Copies of the prospectus supplement, when available, and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head
9:00 AM ET 2/6/24 | BusinessWire
Marks key achievement that is a prerequisite to filing a Biologics License Application with the FDA and other regulators for marketing approval
VIENNA, Va.--(BUSINESS WIRE)--February 06, 2024--
CEL-SCI Corporation (NYSE American: CVM) today reported that its Multikine(R) (Leukocyte Interleukin, Injection)* cGMP state-of-the-art dedicated manufacturing facility commissioning has been completed.
"This is a very significant milestone in bringing Multikine to market since the manufacturing facility is part of a planned Biologics License Application required for approval of Multikine in the treatment of head and neck cancer," stated CEL-SCI's CEO Geert Kersten.
"The high degree of complexity involved in manufacturing Multikine has required tremendous investment and time on CEL-SCI's part. Our manufacturing trade secret, capability, and know-how are high-value key strategic assets that would be very difficult for others to replicate. This achievement marks a very big step towards the preparation of Multikine for marketing approval," Kersten added.
Originally constructed to supply Multikine for the world's largest global pivotal Phase 3 trial in locally advanced squamous cell carcinoma of the head and neck, CEL-SCI's facility has been expanded and upgraded in preparation for the Company's submission of Multikine for regulatory approval and commercial scale manufacturing. In keeping with CEL-SCI Validation Master Plan, industry standards, International Society for Pharmaceutical Engineering (ISPE) guidelines, International Conference for Harmonization (ICH), and in compliance with regulatory guidelines, CEL-SCI undertook commissioning and qualifying the facility's utilities, systems, and equipment.
About CEL-SCI Corporation
CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. In a Phase 3 study, CEL-SCI studied patients who were newly diagnosed with locally advanced primary squamous cell carcinoma of the head and neck (oral cavity and soft-palate) with the investigational product Multikine administered first, before they received the standard of care, which involved surgery followed by either radiation or chemoradiation. The Phase 3 study enrolled 928 patients. Our approach is unique because most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed.
After analyzing data from the Phase 3 study, we have better defined the target population, which is advanced primary head and neck cancer patients with no lymph node involvement and with low PD-L1 tumor expression. In the Phase 3 study, we observed statistically significant survival data in the final target population, showing that Multikine cut the risk of death in half at five years vs control. We plan to submit the proposed study protocol to the FDA in Q1 2024, with the goal to get FDA buy-in for a confirmatory clinical trial, and also to discuss potential accelerated approval pathways.
Multikine (Leukocyte Interleukin, Injection) received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.
The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the progress and timing of, and the amount of expenses associated with, our research, development and commercialization activities for our product candidates, including Multikine; (ii) our ability to duplicate the clinical results demonstrated in clinical studies, (iii) the timely development of any potential products that can be shown to be safe and effective, (iv) receiving necessary regulatory approvals, (v) difficulties in manufacturing any of the Company's potential products, (vi) our liquidity and ability to raise the necessary capital on acceptable terms, if at all. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the fiscal year ended September 30, 2023 filed with the SEC on December 21, 2023 and the other reports we will with the SEC. You are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this press release. As a result of these matters, changes in fact, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. The forward-looking statements made in this press release are made only as of the date of this press release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances.
* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206088192/en/
CONTACT: Gavin de Windt
CEL-SCI Corporation
(703) 506-9460
SOURCE: CEL-SCI Corporation
Copyright Business Wire 2024
I dunno. I'm not a shareholder or planning to buy any shares. Just a somewhat interested observer.
From what I've seen of the past, there have been many fake outs and lost promises.
I'm too lazy on this one to make the effort to truly determine if it's a real company or not.
With that said, currently they are going to continue to lose a lot of money per share for quite some time, but technically, there is no resistance until (I'll say) somewhere just over $7.
Personally, I'm not a buyer of stocks that lose money.
NEWS OUT- causing stock to be “in-play” and going up
https://feeds.issuerdirect.com/news-release.html?newsid=7643495042413725
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
CEL-SCI has cleared a significant hurdle that mandates cancer drugs in Europe comply with strict requirements for pediatric usage and clinical evidence
CEL-SCI Corporation (NYSE American: CVM) today announced that the European Medicines Agency (EMA) Paediatric Committee granted CEL-SCI a product-specific waiver of strict requirements for commercialization of cancer drugs in the European Union (EU). According to the opinion letter:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131910101/en/
The volume was back in October. The short term chart does show the potential for a decent move. ...with a stop loss at $2.20
Nice move today on decent volume. Something brewing??
I had to laugh when I read your post and then saw your “signature” quoting Tolstoy about patience. Lol.
And more nothing and it's almost February,....
It has bounced upwards off support. Wouldn't panic yet.
As soon as I bought this is goes down
Merck has trailing 12 months total revenue of $59.3 billion. Its yearly revenue from Keytruda is $20.9 billion. Merck is not the same company without Keytruda. It has been demonstrated that the collaborate use of MultiKine and Keytruda would extend the patent on Keytruda by 5 years-which is expiring in 2028. Keytruda works with a high PD-L1 marker (30% of patients) and MK works with a low PD-L1 marker (70% of the patient population). This collaboration appears perfectly suited, and so, inevitable.
Considering support is at $2.45, you may be right .....today. Maybe not tomorrow though.
Very dumb to sell here. January ema feedback saying yes to immediate approval puts this at $30 minimum
Well - doesn't look that we are going to hold above $3 for the moment anyway. I'll be pleasantly surprised though if we do. However, it does generally look like the company is heading the right directions going into 2024.
Thanks for the reply. This seems to pop every once in a while for no reason and then settles back down to where it started. 🤷♂️
My Jan 2,00 options with a few weeks to go are up 85% since purchase....trying to get into 2024 before selling
Nothing going on that I am aware of. I don't expect to hear anything too interesting before Q2 of 2024 other than they might have to raise another small bit of operating capital during Q1. That ~$5MM that they raised back a couple of months ago is about what their corporate cash burn rate per quarter has been the last year or so.
Their corporate 2023 EOY report documents came out on the 22nd - maybe somebody just noticed it?
Any idea for the move up? Thanks in advance
It's certainly nice to see this stock nudging back over $3/share again. $3.08 as of this writing and good volume as well.
Correct analysis on the data. And with CVM getting the nod from Britain's NHS to advance the study of Multikine, they are getting closer to approval in the Us and the EU.
There was still 1 hurdle after Cel-Sci released their Phase 3 data for MultiKine. Because MK did not work with Chemotherapy it was unclear how to "write the (prescription) label" in pharma speak. By identifying the PD-L1 protein reaction this issue was solved. Simply put, anyone on a single doctor's visit can receive a routine and established P.E.T. scan and biopsy and know within 24 hours if they can/should receive MultiKine. The patients prescribed MK will have: 1) A 73% chance of living 5 years or longer. 2) The risk of death is cut by more than half at 5 years. 3) A large percentage of MK recipients will see a reduction in tumor size and stage (II, III, or IV) of the cancer. No new test or cost are required. Regulatory conditional approval pathways now exist for reasons exactly like MK. The toxicity profile of MK is nearly perfect.
Back to $15-$25-$35 per share. Booyah!!
And don’t forget there is a shelf life. I can’t remember exactly but it’s around a year. If they get conditional approval and start pulling in some money they can produce their product and get ahead on their schedule
Who needs the FDA?
Once UK gives the go ahead for conditional approval, were off to the races.
Europe will not stand by and watch its citizens cross the pond to get help.
When Europe gives the go ahead for their 140,000+ new cases each year, CVM will be maxed out on their capability to produce Multikine (20,000) till they build another facility. Depending on the agreements with UK and Europe, their looking at 1.5-2b yearly revenue.
2B in potential cancer drug sales is nothing to sneeze at and Big Pharma knows this. Especially with other cancers to follow.
There will be a buyout early on.
Nope. You can leave. Are you a member of the IHUB trash pickup? My can is overflowing with penny stock posters
Must we endure the rubbish discussed? (As the violins play in the background.)
I tripled by investing, holding and then selling when able to do so for a profit. At times I was stuck many years in between. I am slow because I can't time the market. Some people can do just that. They must have tips or some kind of heads up which I do not. Oh I stay away from all OTC stocks now and have done so for many years. Rule 115 did apply, but it was by accident on my part LOL.
Well, don't know how many years it took to triple but there is the rule 115.
I suggest the slow and steady method....and stay far from penny stocks.
Anytime and you are welcome. Glad you try to help others because I could certainly use some help. Not easy guessing stock picks all the time. I know there is a system and skill in some way. Took me many many years to work $600 into $15,000 by guessing - and of which was an initial investment of $5,000. Not very profitable considering the time spent. I only tripled my money before taxes.
Well I appreciate that. Surprisingly, you are correct about me. I try to help people, but apparently, being a "basher" is a thankless job. Even though I'm typically right.
That is funny. I know deep down you are a nice person. I give credit where it is deserved. I shoot straight. It's the way I am.
How dare you be complimentary to me!
Just hundreds in it. But actually it does matter to me because hundreds of dollars is alot of money for me. And believe it or not I do honestly know that you are a better stock trader than I will ever be. I am sure you know way more than I do. I do compliment you on your success, something I never picked up myself. A skill like yours is something I only can wish I knew. Some have it and most don't. I do not unfortunately.
So then, you don't have "thousands" in it?? So, does it really matter?
The reality of penny stocks is you don't want to put a lot of money into something so high risk, so why do it at all?
Unless I plan on holding a stock for no more than a couple days (because I'm expecting good earnings), I'm looking at it for the long haul, and that certainly wouldn't be a penny stock.
Cel-Sci Corporation (CVM)
https://www.youtube.com/watch?v=auAihG3rtC4
Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.
Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.CANCER - MULTIKINE
Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties. More...INFECTIOUS DISEASES - L.E.A.P.S.(TM)**
L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.
This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform. More...* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products
Partnering Philosophy & Corporate Partners
CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of:
CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.
Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.
CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.
Current Corporate Partners:
a. | Agreement Signed August 2008 | ||
b. | Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011. | ||
c. | Revenue Share | ||
d. | Website - http://www.tevapharm.com/ |
a. | Agreement Signed November 2000 | ||
b. | Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008. | ||
c. | Revenue Share | ||
d. | Website - http://www.oep.com.tw/ |
a. | Agreement signed August 2011 | ||
b. | Territory - Argentina and Venezuela | ||
c. | Revenue Share | ||
d. | Website - http://www.gp-pharm.com/ |
Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology. The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.
* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.
http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833http://stockcharts.com/freecharts/gallery.html?CVM
http://finance.yahoo.com/q?s=cvm&ql=1
https://frugalnorwegian.com/cvm Insight into CVM P3 Trial Results
https://www.cvmresearch.com Insight into CVM P3 Trial Results & FDA Chances of Approval
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |